Immunai Funding: $300M Raised, Series B (2023)

Immunai funding overview

Immunai is based in New York. Immunai has raised $300M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in July 2023. The round record for Immunai runs through 2023; nothing later has been disclosed. Investors on record include Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON and 3 others. 9 distinct backers are named across the disclosed rounds.

Immunai at a glance

Total raised: $300M
Latest round: Series B
Latest round date: July 2023
Headquarters: New York
Notable investors: Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, Tal, Viking Global Investors

Frequently asked about Immunai funding

How much has Immunai raised?: Immunai has raised $300M in total disclosed funding across the rounds on record.
Who has invested in Immunai?: Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON are named among the investors backing Immunai.
What was the latest Immunai funding round?: The most recent disclosed round is a Series B, announced in July 2023.
Where is Immunai based?: Immunai is based in New York.
When did Immunai last raise?: The last disclosed Immunai round closed in July 2023 at Series B.

Round data for Immunai is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in New York and backer lists below.

Immunai Funding: $300M Raised, Series B (2023)

Immunai funding overview

Immunai at a glance

Frequently asked about Immunai funding

Companies related to Immunai (36)

Browse related funding lists (7)